In a report published Friday, Wedbush reiterated its Neutral rating and $5.00 price target on Sequenom SQNM.
Wedbush noted, “SQNM posted 4Q12 sales of $34 MM and a loss of ($0.29), which topped our revenue estimate of $33 MM and missed our EPS loss estimate of ($0.22). Results topped Wall Street consensus revenue estimates of $32 MM and missed the EPS loss estimate of ($0.23). Importantly, it appears to us that 4Q12 MaterniT21 revenue exceeded the Street's expectations by about $1 MM.”
Sequenom closed on Thursday at $4.49.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in